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THE IMPORTANCE OF ECONOMIC EVALUATIONS IN THE ASSESSMENT OF
REIMBURSEMENT APPLICAITIONS
Jacobi M1, Orrskog S2, Medin E2
1Karolinska Institutet, Stockholm, Sweden, 2Heron Evidence Development AB, Stockholm, Sweden
OBJECTIVES: According to the Swedish Healthcare Act, any decisions for prioriti-
sation in health care should be based on three principles; the principle of human
dignity, the principle of need and solidarity, and the principle of cost-effectiveness.
The principle of human dignity is superior to the two other principles and the
cost-effectiveness principle is subordinate to the other two. The Swedish Dental
and Pharmaceutical Benefits Agency (TLV) must prioritise accordingly when as-
sessing whether a pharmaceutical should belong to the reimbursement system.
This study aims to investigate the importance of economic evaluations in decisions
for admission of pharmaceuticals to the reimbursement scheme. METHODS: A
review of all TLV decisions regarding admission to the reimbursement system
dated January 2011 to March 2012 was conducted. The information extracted in-
cluded e.g. decision outcome, type of economic evaluation employed and consid-
ered medical need. Subsequently, the reasons behind the decisions were analysed.
RESULTS:A total of 100 individual decisions for reimbursement were assessed. The
vast majority of the 69 decisions leading to general reimbursement were made
based on the result of an economic evaluation and a great medical need was the
second most important reason. All of the eight negative decisions referred to the
inability of the product to be considered a cost-effective alternative. The main
reasons behind the 23 decisions for restricted reimbursement were a great medical
need and that the product was cost-effective alternative for a specific subgroup.
Hence, it appears that the principle for cost-effectiveness is considered more im-
portant than the principle of human dignity as medical need was the second most
common reason for general reimbursement. CONCLUSIONS: The principle for
cost-effectiveness appears to be the most important principle in decisions around
a pharmaceutical’s admission to the reimbursement system, although the princi-
pal’s subordinate position to the principle of human dignity and the principle of
need and solidarity.
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REVIEW OF COST EFFECTIVENESS STUDIES OF HIGH BUDGET IMPACT DRUGS
(2007-2012)
Aggarwal S
Novel Health Strategies, Bethesda, MD, USA
OBJECTIVES: The recently made coverage decisions by UK’s NICE, Scotland’s SMC
and the allocation of $1.1 billion for comparative effectiveness research by the
United States, are strong indicators of trends in pricing and reimbursement that
are likely to be observed in the future. To gain an additional insight into these
trends, we analyzed the cost effectiveness studies for the top twenty highest selling
drugs ($90-100B worldwide sales) METHODS: The Top 20 drugs were selected
based on their worldwide sales. For this analysis, we segmented these drugs into
categories as primary care, specialty, small molecules, biologics, therapy areas and
availability of generic alternatives. We analyzed the cost effectiveness studies that
were published in peer-reviewed journals. Search was conducted using generic
names of the drugs and the phrase “cost effectiveness” in abstract of the published
study. RESULTS: During 2007-2012, the number of published studies on “cost ef-
fectiveness” have increased by more than 32%. There is a large variability in CERs
for same drugs for different indications, in some cases also varying by biomarkers.
Primary care drugs had lower and less variable CERs than specialty drugs. Varia-
tions also exist in methodology used by different groups in modeling cost effec-
tiveness, especially for time horizon and comparator. Majority of primary care
drugs were modeled for a time horizon of 35-40 years or lifetime to demonstrate
cost effectiveness. CONCLUSIONS: This analysis shows the range, variability and
methods used for calculation of ICER values for these high budget impact drugs and
provides lessons for executives and policy makers.
PHP115
THE SHARP DECREASE OF DRUG’S ACCESS TO REIMBURSEMENT IN FRANCE IN
2011
Hounkanlin H, Troubat A, Morlet Vigier D
IMS Health, Puteaux, France
OBJECTIVES: In France, all drug’s indications are listed for reimbursement accord-
ing to the advice of the Haute Autorité de Santé (HAS), which assesses the SMR level
(Service Medical Rendu) – linked to the future drug reimbursement level, the ASMR
(comparative added value) – linked to the future price and “official” target popula-
tion. Until last year, 90-95% of SMR levels allowed reimbursement, hence a signif-
icant manufacturer focus on ASMR level (which actually is the basis for reimbursed
drugs price fixation). Following the “Mediator affair” in 2010, the HAS perceived
high percentage of positive recommendations for reimbursement have been chal-
lenged by multiple administrative and political reports. We investigated the 2011
HAS recommendations for reimbursement of new drugs/indications. METHODS:
We considered all complete procedures for a first inscription or line extension with
an HAS opinion published between Jan and Dec 2011. We also considered applica-
tions which have been withdrawn by companies (no HAS advice). We focused our
analysis on the SMR level, indication by indication, and compared it to 2010 HAS
opinions. RESULTS: Sixty-two HAS opinions have been published in 2011: 30% less
than in 2010 (85 opinions in 2010). Regarding the SMR and considering it is granted
indication by indication: out of 81 SMRs granted for a first indication reimburse-
ment, 30% (24) were considered “insufficient” (no reimbursement)–in 11 of these
cases companies withdrew their applications. In 2010, the SMR “insufficient” rep-
resented only 11% of all the published advices (which was already higher than 2009:
6%). CONCLUSIONS: The number of positive recommendations for reimbursement
has sharply decreased in 2011 versus 2010, going from 6-10% in previous years to
over 30%. A qualitative analysis shows that the HAS seems to have evolved the
assessment criteria used for SMR.
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ORPHAN DRUG PRICING AND ACCESS – CURRENT SITUATION AND FUTURE
TRENDS IN EU
Jeffery M, White R
Access Partnership, London, UK
OBJECTIVES: In recent years, several European countries have made changes to
their policies related to HTA, pricing and market access, funding and cost reduc-
tion. This has impacted orphan drugs and this will continue in the future. The
objective of this research is to assess the current and future orphan drug pricing
and reimbursement environment analyzing the changing dynamics from all
perspectives.METHODS: Interviews were conducted with a variety of stakeholders
including payers, academics, and KOLs in France, Italy, Germany, Spain, the UK,
Sweden, Romania, Poland and the Netherlands. Comparisons were also made with
other mature markets such as Australia, and the US. RESULTS: Orphan definitions
vary from 5 in 10,0000 in EU to 1.2 in 10,000 in Australia. Pricing, payment and
regulations mechanisms demonstrate variability across countries including finan-
cial incentives, protocol assistance, fast-track procedures and market exclusivity.
There is lack of clarity at the EU as well as country level. For instance according to
AMNOG law in Germany, products with less than €50 million budget impact are not
expected to be assessed. However IQWiG did assess orphan drugs in 2011-12. In the
UK, with the introduction of value based pricing in 2014, orphan drug approvals are
likely to improve. The number of orphan drug approvals and the share of pharma-
ceutical spend will increase with as much as 1-2% absolute, current levels being at
approximately 3%. However this may not translate into disproportionate drug
expenditure. Regulatory as well as payers have been accommodative in accepting
sub-optimal clinical data; however in the future this is expected to change.
CONCLUSIONS: Payers are expected to become sensitive to orphan drug data re-
quirements. The drivers of pricing and reimbursement decision will remain the
same at unmet need, disease severity and number of patients; however the ex-
pected magnitude of clinical effectiveness of the drug will be higher.
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SMC DECISIONS: ARE THEY GETTING TOUGHER?
Morawski J
Quintiles Consulting, Hoofddorp, The Netherlands
OBJECTIVES: To investigate whether trends exist in NHS drug funding decisions in
Scotland over recent years.METHODS: In 2008, the Scottish Medicines Consortium
(SMC) published an annual report illustrating drug submission statistics for that
year. No further annual reports or related data has been published by the SMC since
then. In the absence of such reports, a quantitative analysis was performed includ-
ing all SMC appraisals published between January 2008 and December 2011 to
investigate whether any trends exist in the decisions rendered by the SMC. The
analysis was first performed on all submissions in total and then by submission
type. RESULTS: On average 80 (range 73 – 88) submission assessments were per-
formed by the SMC per year. The proportion of decisions granted by the SMC over
the four years was relatively stable with an average of 37%/ 32%/ 31% accounting for
full recommendations/ restricted recommendations and non-recommendations.
In the abbreviated submission process, the proportion of recommended submis-
sions has decreased gradually (20 [80%] abbreviated submissions in 2008 to 8 [50%]
in 2011) with a parallel increase in restricted recommendations (4 [16%] in 2008 to
8 [50%] in 2011). The number of non-submissions has also increased progressively
over the last three years, accounting for 19% of assessments performed by the SMC
in 2011. High variations in the proportion recommendations (range 14 – 38%) and
restricted recommendations (range 11 – 43%) granted for resubmissions were ob-
served across the years. CONCLUSIONS: The analysis shows that over the four
years investigated, the proportion of recommendations, restricted recommenda-
tions and non-recommendations granted for reimbursement submissions in Scot-
land remained fairly consistent. At a closer look, clear trends were evident for
abbreviated submission decisions. Eventually around 85% of SMC submissions will
receive funding through either a full recommendation, restricted recommendation
or resubmission recommendation.
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ESTIMATING THE PROBABILITY OF A RECOMMENDATION FOR
REIMBURSEMENT FOR A NEW DRUG IN THE UK USING AN MCDA APPROACH
Williams P1, Mauskopf JA1, Kilburg A2, Lebiecki J2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI Health Solutions, Manchester, UK
OBJECTIVES: To develop a quantitative process to estimate the probability of a
recommendation for reimbursement for a new drug with a cost per QALY of be-
tween 20,000 and 30,000 pounds in the UK.METHODS:A multi-criteria process was
used that included: selection of 7 UK decision makers; pre-workshop question-
naires to identify the most important attributes for the decision and their relative
importance; a workshop to develop levels for the most important attributes, map
each attribute level to a value function and identify marginal drug profiles (drugs
just acceptable for a recommendation for reimbursement); post-workshop estima-
tion of weighted scores for each marginal product based on the estimated values
and relative importance of their attribute levels and a logistic regression model to
estimate the probability of a favorable reimbursement recommendation as a func-
tion of the weighted scores; post-workshop questionnaire to validate the logistic
model using participant ratings for a series of hypothetical products. RESULTS:The
most important attributes identified for a recomendation for reimbursement and
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their relative importance weights (%) were: robustness of clinical evidence (31%);
robustness of CE estimates (25%); availability of alternative treatments (8%); incre-
mental efficacy (8%); relative safety (7%); ease of adoption (7%); incremental impact
on QOL (5%); budget impact (4%); unmet need (3%); size of population (1%). The
attribute levels and relative value for a positive reimbursement recommendation
(0-1) for the most important attribute, robustness of clinical evidence, were: ‘end-
points and/or comparators not relevant to payers’ (0); ‘weak intermediate clinical
endpoints, indirect comparisons needed’ (0.25); ‘all clinical endpoints and compar-
ators relevant for NHS’ (1). The estimates of the probability of a favorable reim-
bursement recommendation for the hypothetical products included in the post-
workshop questionnaire using the logistic regression model had 71% positive
predictive value and 91% negative predictive value when compared to participant
decisions for these hypothetical products provided in responses to the post-work-
shop questionnaire. CONCLUSIONS: An MCDA process can provide both a qualita-
tive understanding and quantitative estimates of the relative importance, attribute
levels, and value scales of different product attributes that influence a positive
reimbursement decision in the UK.
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VALUE AND THE MULTIPLE CRITERIA USED IN OECD COUNTRIES’ MEDICINE
REIMBURSEMENT DECISION-MAKING PROCESSES USING HEALTH ECONOMIC
EVIDENCE
Bending MW, Smith TA
MAPI Consultancy, London, UK
OBJECTIVES: The meaning of ‘value’ and the criteria for judging it are increasingly
being debated in countries with established reimbursement processes using
Health Technology Assessment (HTA). The objective of this study is to determine
the criteria used in decision-making to determine value in OECD countries’ deci-
sion-making processes using health economic analysis (HEA).METHODS:A review
of reimbursement agencies’ websites, relevant literature and contact with individ-
ual agencies identified the criteria used to determine value for medicines in pro-
cesses using HEA. Countries are categorised by how HEA is used in decision-mak-
ing processes, nature of the cost-effectiveness threshold range (explicit, implicit,
no threshold), threshold range where identified and the use of such evidence
alongside other decision-making criteria (burden of disease, severity, innovation
and others). Details of the judgments reported with respect to the criteria in doc-
uments justifying the decision are examined. RESULTS: Twenty-four OECD coun-
tries use formal HTA of which 17 require HEA in submissions for certain medicines.
Cost-effectiveness thresholds are identified in nine countries, explicitly stated in
three. Implicit threshold ranges are identified in four (based on past decisions),
whilst in two implicit willingness-to-pay thresholds are used for decision-making.
Use of HEA is always accompanied by other criteria (severity, need, burden of
disease, end of life, innovation, amongst others). Some countries use cost-effec-
tiveness thresholds central to their decision-making, some report them equally
amongst other criteria, whilst in others it is unclear how such criteria is judged.
Details relating to the judgement of criteria used in appraisals are sparse.
CONCLUSIONS: Multiple criteria are common in countries using HEA, although
some are country specific. Reporting of these criteria and their respective use and
interpretation alongside the cost-effectiveness threshold range suggests variation
in the meaning of value. Multi-criteria decision analysis could provide clarity in the
justification of the reimbursement decision and the meaning of value.
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NEW PRICING DYNAMICS IN BIG FIVE EU: CASE STUDY OF BIOSIMILAR GM-CSF
PRODUCTS
Aggarwal S
Novel Health Strategies, Bethesda, MD, USA
OBJECTIVES: During 2011-2012 significant price cuts were implemented in various
markets in the European Union. These price cuts have introduced new pricing
dynamics affecting reference pricing and intra-EU parallel export of expensive
drugs. METHODS: To understand new pricing dynamics in the big five EU (UK,
France, Germany, Italy and Spain) we analyzed the trend in pricing for branded and
biosimilar GM-CSF products. Prices were analyzed for percentage discount com-
pared to branded GM-CSF product and relative price levels in five selected markets.
Recent reimbursement policy changes, and price cuts were also analyzed.
RESULTS: The 2012 prices for GM-CSF products show significant variation across
UK, France, Germany, Italy and Spain. The prices for GM-CSF products were dra-
matically lower in Spain and UK compared to France, Germany and Italy. For ex-
ample, for branded GM-CSF product prices in Spain were 80% lower than prices in
the UK. Similarly, the prices for biosimilar GM-CSF products were 72% lower in
Spain than in the UK. The percentage price discount for biosimilar products versus
branded product also shows large variation in big five EU markets. For example,
Spain and UK prices were almost at parity while the prices in France, Germany and
Italy showed 12%, 31% and 26% discount, respectively.CONCLUSIONS: Recent pric-
ing reforms have significantly changed the pricing dynamic across big five EU
markets. Case study of GM-CSF products illustrates wide variation in pricing for
branded and biosimilar products.
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DRUG REIMBURSEMENT MAINTENANCE: A FRENCH CHALLENGE IN 2011
Hounkanlin H, Troubat A, Morlet Vigier D
IMS Health, Puteaux, France
OBJECTIVES: In France, reimbursement of drugs is based on the therapeutic value
of drugs (SMR level for each indication) as assessed by HAS, going from “insuffi-
cient” (no reimbursement at all) to “weak” (15% reimbursement), “moderate” (30%)
and “important” (65%). HAS and manufacturer have the right to ask for re-assess-
ment anytime after the initial reimbursement listing; in all cases, a relisting pro-
cess is compulsory every 5 years. We analyzed HAS’s reassessment and relisting
activity over the year 2011, based on the hypothesis that the Mediator safety “af-
fair” would have impacted the process. METHODS: We considered all complete
procedures for relisting, re-assessments and class reviews and focused on drugs for
which a HAS advice was published between Jan and Dec 2011. We compared pre-
vious and new SMR levels for each indication. RESULTS: Twenty-six drugs have
gone the relisting process, corresponding to 33 different indications, out of which
31 cases were analyzable: HAS modified 14 SMRs while 17 SMRs remained un-
changed. Almost 50% (6/13) of SMR initially rated as “important” were changed to
“insufficient” (4) or “moderate” (2). All initially insufficient SMR (8) were confirmed.
19 drugs have gone through re-assessment process, corresponding to 24 SMRs/
indication, out of each only 21 were analyzable: 10 SMRs have been modified (only
2 increased and the rest lowered) and 11 unchanged. In 8 of these cases, the man-
ufacturer had asked for the re-assessment. 6 full therapeutic classes have been
reviewed in 2011, including Alzheimer’s and antipschychotics, resulting in a har-
monization and a decrease of the SMR levels. CONCLUSIONS: Manufacturers
should now ensure that reassessment and relisting dossiers in France incorporate
as much of relevant clinical, safety and real-life information as possible in order to
maintain the reimbursement level.
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THE USE OF QUANTITATIVE AND QUALITATIVE CRITERIA FOR MAKING DRUG
FUNDING DECISIONS
Rübesam T1, Jain M2
1University of Gloucestershire, Cheltenham, UK, 2BioMarin Europe Limited, London, UK
OBJECTIVES: Every day health care decison makers on the national, regional and
local level face the challenge of making complex funding decisions. The complexity
in drug funding decisions comes from balancing quantitative criteria such as clin-
ical evidence and qualitative criteria such as personal experience of decison mak-
ers. This systematic literature review reflects the research status on applied criteria
in drug funding decisions. METHODS: Relevant literature has been identified by
using a systematic database search process as described by Tranfield, Denyer &
Smart (2003) via EBSCO and Science Direct. Topic relevant search terms were ap-
plied which resulted in 412 papers. Detailed screening of the paper abstracts with
application of inclusion criteria reduced the number of relevant papers down to 20.
Following this, information from those 20 papers has been analysed and compared
to practitioner experience. RESULTS: The most discussed criteria with influence on
drug funding decisions were the importance and use of economic evaluations and
the importance of political and social factors for the decision process. Both topics
were discussed in six studies (30% each). More than half of the studies (14 out of 20)
showed evidence that drug funding decisions are decided not only by quantitative
criteria, but also decided by qualitative criteria. Another finding was a geographical
research prioritization. The most discussed country in the relevant studies was the
UK (23%) followed by Canada (15%), the Netherlands (13%), Australia, France and
the USA (each 10%). CONCLUSIONS: Relevant research literature shows the exis-
tence of quantitative criteria influencing drug funding decision-making but also
the use of qualitative criteria seems to be proved. Although this is seldom docu-
mented publicly, qualitative criteria are shown to have an impact on drug funding
decisions. Further research work is necessary to extend knowledge about the im-
pact of qualitative criteria in drug funding decision-making.
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IMPORTANCE OF HEALTH-RELATED QUALITY OF LIFE AS AN ENDPOINT IN
BENEFIT ASSESSMENT ACCORDING TO THE GERMAN AMNOG
Koester C1, Kossmann B1, Boehm K1, Wasem J2, Aidelsburger P1
1CAREM GmbH, Sauerlach, Bavaria, Germany, 2University Duisburg-Essen, Essen, Germany
OBJECTIVES:Health-related quality of life (HRQoL) might be one important patient
reported endpoint (PRO) in determining the additional benefit of pharmaceuticals
recently evaluated according to the newly established German law for reforming
the market for pharmaceuticals (AMNOG). A comparative analysis is performed to
gain insight how HRQoL was implemented in the benefit dossier by the pharma-
ceutical manufacturer on the one hand and how it was assessed in the benefit
assessment by the Institute for Quality and Efficiency in Health Care (IQWiG) on the
other hand. METHODS: We reviewed 23 published benefit dossiers and the corre-
sponding benefit assessments, which the IQWiG performed since the implemen-
tation of the AMNOG in 2011. Corresponding statements concerning HRQoL in
benefit dossiers and benefit assessment were faced narrative. RESULTS: Eighteen
benefit dossiers reported HRQoL and a number of validated instruments were used,
which were generally accepted by the IQWiG if not for major mistakes in the benefit
dossiers (for example the use of another appropriate comparator). Overall, the
pharmaceutical manufacturers have difficulties to clearly prove an additional ben-
efit due to HRQoL because the used studies do not contain data on this endpoint or
the results are statistical non-significant. The IQWiG draws a similar conclusion as
the pharmaceutical manufacturers and attests none of the benefit dossiers an
additional benefit due to HRQoL. A common methodological problem reported in
the benefit assessments is for example a low response rate so that the data has high
bias potential. CONCLUSIONS: None of the published benefit assessments state an
additional benefit in HRQoL although this is an important PRO and the pharmaceu-
tical manufacturers presented a range of accepted validated instruments to assess
it. Dealing with data uncertainties concerning the HRQoL has to be accomplished in
the future of the benefit assessment.
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COMPARISON OF HTA DOSSIER REQUIREMENTS ACROSS EUROPE
Casamayor M, Van Engen A
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